Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

A Study in Healthy Participants With Elevated LDL-C to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS060380

12. November 2026 aktualisiert von: Cascade Pharmaceuticals, Inc

A Randomized, Double-blind, Placebo-controlled, Sequential, Multiple Ascending Dose (MAD) Study Following Oral Administration in Healthy Participants With Elevated LDL-C to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS060380

A study in Healthy Participants with Elevated LDL-C to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS060380.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

This is a randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, PK and PD of CS060380 following oral multiple ascending dose administration in healthy participants with elevated LDL-C.

Approximately 30 participants (10 participants per cohort: n=8 participants will receive active CS060380 and n=2 participants will be administered placebo) will be enrolled sequentially in 3 ascending dose groups. The proposed dose levels will range from 1.0 mg to 4.0 mg.

The next higher dose cohort will be enrolled only after the prior dose cohort has been discharged from the CPC on Day 17 and the SRC has reviewed all available safety/tolerability, PK/PD, and thyroid function data.

Studientyp

Interventionell

Einschreibung (Geschätzt)

30

Phase

  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 65 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. The participant provided signed and dated informed consent.

  2. Male or female aged 18-65 years (inclusive).

  3. Fasting LDL-C >110 mg/dL (2.85 mmol/L) at screening.

  4. Female participants must meet one of the following:

    1. Postmenopausal status confirmed by follicle-stimulating hormone (FSH) testing, or
    2. Surgically sterile (medically documented), or
    3. If with childbearing potential, the participant must agree to use at least one highly effective contraceptive method in combination with an additional effective contraceptive method from study initiation until 3 months after the last dose, or
    4. Complete abstinence (if agreed by the participant).

    Male participants, even if surgically sterilized (e.g., vasectomy), must:

    1. Use effective barrier contraception and refrain from sperm donation throughout the study and for 3 months after the last dose, or
    2. Complete abstinence (if agreed upon by the participant). Refer to Section 9.4 for detailed contraceptive requirements.
  5. Normal renal function (estimated glomerular filtration rate [eGFR] ≥ 80 mL/min/1.73 m², calculated using the CKD-EPI equation).

  6. Good general health, as judged by the Investigator based on: medical/surgical history, complete physical examination, vital signs, laboratory tests, and 12-lead ECG results (all findings either normal or with no clinically significant abnormalities).

  7. No significant medical history; assessed to be in good general health at screening, with evaluations completed ≤ 28 days before the first dose.

  8. Willingness and ability to: Understand and comply with study procedures/restrictions, complete the trial as planned and communicate effectively with the Investigator.

Exclusion Criteria:

  1. Individuals with special dietary requirements unable to comply with standardized diets.

  2. Females who are pregnant or lactating, those with pregnancy plans within 3 months post-trial, or female participants with positive pregnancy tests during screening/baseline periods.

  3. Participants with febrile illness or active infection within 7 days prior to the first dose of the investigational drug.

  4. Participants with positive urine drug screening results.

  5. Participants with a history of drug/substance abuse within 5 years prior to the trial or positive drug screening at Day -1.

  6. Participants receiving lipid-lowering therapy or with LDL-C > 190 mg/dL, or those with a history of coronary artery disease, cardiac arrhythmias, unexplained syncope, or family history of sudden cardiac arrest.

  7. Participants with a history of QTc prolongation:

    1. QTcF ≥ 450 ms during screening;
    2. Hypocalcemia or family history of long QT syndrome;
    3. Use of QT/QTc-prolonging medications;
    4. ECG abnormalities deemed clinically significant by the Investigator.
  8. Tobacco or nicotine product use within 3 months prior to screening or during the study until discharge.

  9. Use of other investigational drugs within 40 days prior to enrollment or within ≥ 5 half-lives (whichever is longer).

  10. Positive infectious disease screening results during screening (HIV antibody, HBsAg, HCV antibody).

  11. Clinically significant laboratory abnormalities per Investigator judgment during screening.

  12. Presence of clinically significant hypertension, defined as systolic blood pressure (SBP) > 145 mmHg and/or diastolic blood pressure (DBP) > 90 mmHg, at Screening or Admission.

  13. Blood loss > 50 mL within 40 days or > 500 mL within 56 days prior to dosing.

  14. Regular alcohol consumption (> 1 unit/day) within 1 month prior to screening or positive alcohol test at screening or admission. [1 unit = 150 mL wine, 360 mL beer, or 45 mL 40% alcohol]. Alcohol consumption within 48 hours predose or during CRU stays.

  15. Prescription/OTC medication use within 14 days prior to admission (Day -1) or ≥ 5 half-lives (whichever is longer); or use of any of the inhibitors or induces as listed in Appendix 1, CYP3A-, p-glycoprotein- (p-gp) or breast cancer resistance protein (BCRP)-modulating substances (e.g., herbs, grapefruit) within 14 days predose or ≥ 5 half-lives.

  16. Thyroid disease history or clinically significant thyroid test abnormalities.

  17. Hypersensitivity to thyroid medications.

  18. Conditions potentially affecting drug ADME (e.g., gastrectomy, cholecystectomy, inflammatory bowel disease).

  19. Clinically significant comorbidities (e.g., GI, renal, hepatic, neurological, hematological, endocrine, oncological, pulmonary, immunological, psychiatric, or cardiovascular diseases) that may compromise study conduct/interpretation or pose risks per Investigator assessment.

  20. Hypersensitivity to investigational drug components, specific allergy history (asthma, urticaria, eczema), or atopic predisposition (allergy to ≥ 2 drugs/foods like milk/pollen).

  21. Any condition deemed by the Investigator to jeopardize participant safety or study integrity.

  22. Abnormal thyroid function tests (total/free T3, total/free T4, TSH) beyond reference ranges during screening.

  23. Troponin > ULN during screening or Day -1 periods.

  24. Presence of any psychiatric disorder or impaired mental capacity that may compromise the ability to provide informed consent, affect the assessment of efficacy, or impair compliance with the study protocol.

  25. Any other condition that, in the opinion of the investigator, may jeopardize the safety of the subject or compromise the quality of the clinical study.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: MAD Cohort 1: CS060380 1.0 mg

CS060380 1.0 mg will be administered orally once daily (QD) on Days 1-14. Within this cohort (n=10), participants are randomized 8 active : 2 placebo under double-blind conditions.

CS060380 is administered orally once daily (QD)

Matching placebo is administered orally once daily (QD)

Andere Namen:
  • CS060380 Placebo
Experimental: MAD Cohort 2: CS060380 2.0 mg

CS060380 2.0 mg will be administered orally once daily (QD) on Days 1-14. Within this cohort (n=10), participants are randomized 8 active : 2 placebo under double-blind conditions.

CS060380 is administered orally once daily (QD)

Matching placebo is administered orally once daily (QD)

Andere Namen:
  • CS060380 Placebo
Experimental: MAD Cohort 3: CS060380 4.0 mg

CS060380 4.0 mg will be administered orally once daily (QD) on Days 1-14. Within this cohort (n=10), participants are randomized 8 active : 2 placebo under double-blind conditions.

CS060380 is administered orally once daily (QD)

Matching placebo is administered orally once daily (QD)

Andere Namen:
  • CS060380 Placebo

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Adverse Events during the study period
Zeitfenster: Baseline to Day28

To characterize the safety and tolerability of multiple doses of CS060380 in healthy participants

Baseline to Day28

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Cmax
Zeitfenster: Day1

Pharmacokinetics: Maximum concentration during a dosing interval

Day1
Tmax
Zeitfenster: Day1 Day17

Pharmacokinetics: Time to maximum plasma concentration

Day1 Day17
t1/2
Zeitfenster: Day1

Pharmacokinetics: Terminal elimination half-life

Day1
AUClast
Zeitfenster: Day1

Pharmacokinetics: AUC from time 0 to the last measurable concentration

Day1
AUCinf
Zeitfenster: Day1

Pharmacokinetics: area under the plasma concentration-time curve from time zero to infinity

Day1
CL/F
Zeitfenster: Day1

Pharmacokinetics: apparent total plasma clearance

Day1
Cmax,ss
Zeitfenster: Day14

Pharmacokinetics: steady-state maximum plasma concentration

Day14
Cmin
Zeitfenster: Day14

Pharmacokinetics: minimum concentration during a dosing interval

Day14
t1/2,ss
Zeitfenster: Day14

Pharmacokinetics: steady-state terminal elimination half-life

Day14
AUCτ (τ = 24 hours)
Zeitfenster: Day14

Pharmacokinetics: AUC from time 0 to 24 hours after dosing

Day14
CL/Fss
Zeitfenster: Day14

Pharmacokinetics: steady-State apparent total plasma clearance

Day14
DF
Zeitfenster: Day14

Pharmacokinetics: degree of fluctuation

Day14
Cavg
Zeitfenster: Day14

Pharmacokinetics: mean plasma concentration during a dosing interval

Day14
Rac_AUCτ
Zeitfenster: Day14

Pharmacokinetics: accumulation ratio based on area under the plasma concentration-time curve

Day14

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
LDL-C
Zeitfenster: Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17

Pharmacodynamics: low-density lipoprotein cholesterol

Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17
HDL-C
Zeitfenster: Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17

Pharmacodynamics: high-density lipoprotein cholesterol

Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17
TG
Zeitfenster: Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17

Pharmacodynamics: triglycerides

Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17
TC
Zeitfenster: Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17

Pharmacodynamics: total cholesterol

Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17
SHBG
Zeitfenster: Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17

Pharmacodynamics: sex hormone binding globulin

Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17
Total/free T3
Zeitfenster: Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17

To explore the effects on thyroid function parameters of CS060380

Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17
total/free T4,
Zeitfenster: Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17

To explore the effects on thyroid function parameters of CS060380

Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17
TSH
Zeitfenster: Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17

To explore the effects on thyroid function parameters of CS060380

Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Mary Purucker, MD, Pharmaron Clinical Pharmacology Center (CPC), Inc.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. November 2026

Primärer Abschluss (Geschätzt)

15. März 2027

Studienabschluss (Geschätzt)

15. April 2027

Studienanmeldedaten

Zuerst eingereicht

5. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

12. November 2026

Zuerst gepostet (Tatsächlich)

18. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

18. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

12. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • CS060380-MASH-US-I-05

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .